Ranbaxy launches India’s first Remicade biosimilar

By Zachary Brennan contact

- Last updated on GMT

Will this be the first of many biosimilars to hit the Indian market?
Will this be the first of many biosimilars to hit the Indian market?

Related tags: Infliximab

Ranbaxy Laboratories has launched the monoclonal antibody Infimab, the first Remicade (Infliximab) biosimilar, in India -- which is the first what could be a few home-grown biosimilar launches.  

Infimab is being introduced in the Indian market through a licensing partnership with EPIRUS Biopharmaceuticals, and it will be manufactured by Reliance Life Sciences at a facility in Mumbai.

Reliance previously said that its manufacturing facility was inspected and approved in July​. In addition to its contract manufacturing services for mAbs and recombinant proteins, Reliance has its own portfolio of eight biosimilars. Biosimilars for Remicade were also the first approved mAb biosimilars in Europe​.

The innovator reference product from Johnson & Johnson is currently marketed for the treatment of inflammatory diseases including rheumatoid arthritis, Crohn’s Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis.

Ranbaxy says that a Phase III trial met its predefined endpoint and demonstrated the comparability of Infimab to the reference innovator, although a spokesman would not expand on whether Infimab will be launched in other, more regulated markets. The study​ also showed no meaningful differences between Infimab and Remicade ​with regard to safety or immunogenicity.

Rajeev Sibal, VP & Country Head-India Region, Ranbaxy, said,“The product has been developed as per global standards and delivers a similar clinical outcome to the innovator. It will be available in India at a very significant discount as compared to the innovator drug. More Indian patients will get the benefit of a world-class biologic treatment​.”

Other Biosimilars

Meanwhile, other developers in India are eyeing the biosimilar industry as well. Dr Reddy's​ has made a number of investments over the past five years to ramp up production and development of biosimilars.

The investment comes as India back in 2012 unveiled 'similar biologics' guidelines​ to help developers proceed.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars